Home » Stem Cell News » Reactive » CIRM grants $6.4 mn Strategic Partnership Award to Sangamo BioSciences to …

“Sangamo’s powerful and precise ZFN-genome editing technology enables modification of a patient’s own stem cells and potentially provides a safer approach to current therapies for haemoglobinopathies such as beta-thalassemia and sickle cell disease,” …
[Read more]

Comments are closed.

FREE SUBSCRIPTION

Just fill in your email address, we will send you the latest market update periodically.

Contact Us

Name*

Email*

Tel

Message*

captcha

*require